



## Derek W. Barnett, Ph.D.

Patent Agent

Tel 312.423.3440  
dbarnett@marshallip.com

---

Derek W. Barnett, Ph.D. is a Patent Agent prosecuting patent applications in the U.S. and abroad for clients in the chemical, pharmaceutical, and biotechnology arts.

### Practices

- Patent Prosecution

### Industries

- Chemical Sciences

### Representative Experience

Derek has experience with a range of technologies including:

- Small molecules and macromolecules
- Chemical syntheses
- Pharmaceutical compositions
- Therapeutics methods
- Polymers
- Anticancer agents
- Biofuels
- Biosimilars

## Background and Credentials

Derek draws from more than 15 years preparing and prosecuting patent applications and over a decade of education, training, and experience in the scientific field. Derek received his Ph.D. in medicinal chemistry and pharmacognosy from The Ohio State University where he conducted studies in the areas of synthetic organic chemistry, biochemistry, and medicinal chemistry related to the study of vitamin A derived compounds. He received his B.S., *magna cum laude*, in chemistry from the University of Arkansas at Little Rock.

## Education

- The Ohio State University (Ph.D.)
  - Medicinal Chemistry and Pharmacognosy
- University of Arkansas at Little Rock (B.S., *magna cum laude*)
  - Chemistry

## Bar Admissions

- U.S. Patent and Trademark Office

## Community and Professional Involvement

- American Intellectual Property Law Association
- American Chemical Society – *Division of Medicinal Chemistry & Division of Chemistry & the Law*

## Publications and Presentations

2013

**“Chirally deuterated benzyl chlorides from benzyl alcohols via hexachloroacetone/polymer-supported triphenylphosphine: synthesis of protected (2S,3S)-[3-2H,15N]-tyrosine”**

*J Labelled Comp Radiopharm*, 56: 6-11

Issued June 23, 2009

**U.S. Patent No. 7,550,510 (Curley et al. – The Ohio State University Research Foundation) entitled “Solid Phase Synthesis of Arylretinamides”**

2007

**“The unhydrolyzable fenretinide, 4-HBR, induces the proapoptotic genes GADD153 (CHOP) and BBC3 (PUMA) and apoptosis that is caspase-dependent and independent of the retinoic acid receptor”**

*Cancer Research*, 67: 6270-6277

2002

**"Photo/affinity label analogs of N-(4-hydroxyphenyl)retinamide"**

*224th National Meeting of the American Chemical Society, Boston, MA, MEDI 143*

2002

**"Isotopically labeled amino acids: stereochemical implications of hexachloroacetone/polymer supported triphenylphosphine chlorination of chirally deuterated benzylic alcohols"**

*224th National Meeting of the American Chemical Society, Boston, MA, MEDI 404*

2002

**"Stereoselective route to  $^{15}\text{N}$ -labeled- $\beta$ -deuterated amino acids: synthesis of (2S,3R)-3- $^2\text{H}$ , $^{15}\text{N}$ ]-phenylalanine"**

*Tetrahedron: Asymmetry, 13: 1893-1900*

1999

**"Synthetic efforts toward the stereoselective synthesis of  $\beta$ -deuterated amino acids for studies of protein structure by multidimensional NMR"**

*36th National Organic Chemistry Symposium, Madison, WI*

1999

**"Towards a general approach to stereoselectively  $\beta$ -deuterated and  $^{15}\text{N}$ -labeled amino acids: synthesis of (2S,3S)-3- $^2\text{H}$ , $^{15}\text{N}$ ]-phenylalanine"**

*218th National Meeting of the American Chemical Society, New Orleans, LA, MEDI 255*